Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives $86.71 Average Target Price from Analysts

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has been assigned an average recommendation of “Moderate Buy” from the fourteen brokerages that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $86.71.

A number of research analysts have issued reports on RARE shares. The Goldman Sachs Group upgraded Ultragenyx Pharmaceutical from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $56.00 to $67.00 in a research note on Thursday, June 6th. Cantor Fitzgerald reiterated an “overweight” rating and set a $115.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, June 12th. Robert W. Baird lifted their price objective on Ultragenyx Pharmaceutical from $68.00 to $72.00 and gave the company an “outperform” rating in a research note on Friday, May 31st. Wedbush lifted their price objective on Ultragenyx Pharmaceutical from $47.00 to $48.00 and gave the company a “neutral” rating in a research note on Friday, May 31st. Finally, Stifel Nicolaus lifted their price objective on Ultragenyx Pharmaceutical from $124.00 to $127.00 and gave the company a “buy” rating in a research note on Friday, May 31st.

Insider Buying and Selling

In related news, Director Corazon (Corsee) D. Sanders sold 1,737 shares of Ultragenyx Pharmaceutical stock in a transaction on Monday, June 10th. The stock was sold at an average price of $41.10, for a total value of $71,390.70. Following the completion of the sale, the director now owns 7,248 shares of the company’s stock, valued at $297,892.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, EVP Karah Herdman Parschauer sold 9,806 shares of Ultragenyx Pharmaceutical stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $45.00, for a total transaction of $441,270.00. Following the transaction, the executive vice president now directly owns 57,981 shares in the company, valued at $2,609,145. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Corazon (Corsee) D. Sanders sold 1,737 shares of Ultragenyx Pharmaceutical stock in a transaction on Monday, June 10th. The shares were sold at an average price of $41.10, for a total value of $71,390.70. Following the transaction, the director now owns 7,248 shares in the company, valued at $297,892.80. The disclosure for this sale can be found here. Insiders sold 11,685 shares of company stock valued at $518,923 over the last 90 days. Company insiders own 5.80% of the company’s stock.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Several institutional investors and hedge funds have recently bought and sold shares of RARE. Charles Schwab Investment Management Inc. lifted its position in Ultragenyx Pharmaceutical by 5.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 396,725 shares of the biopharmaceutical company’s stock valued at $14,143,000 after purchasing an additional 19,487 shares in the last quarter. FMR LLC lifted its position in Ultragenyx Pharmaceutical by 23.4% during the third quarter. FMR LLC now owns 1,027,785 shares of the biopharmaceutical company’s stock valued at $36,641,000 after purchasing an additional 195,108 shares in the last quarter. Invesco Ltd. lifted its position in shares of Ultragenyx Pharmaceutical by 2.1% in the third quarter. Invesco Ltd. now owns 385,441 shares of the biopharmaceutical company’s stock valued at $13,741,000 after acquiring an additional 8,092 shares in the last quarter. Aigen Investment Management LP lifted its position in shares of Ultragenyx Pharmaceutical by 52.3% in the third quarter. Aigen Investment Management LP now owns 6,732 shares of the biopharmaceutical company’s stock valued at $240,000 after acquiring an additional 2,312 shares in the last quarter. Finally, Hsbc Holdings PLC lifted its position in shares of Ultragenyx Pharmaceutical by 10.9% in the third quarter. Hsbc Holdings PLC now owns 26,975 shares of the biopharmaceutical company’s stock valued at $958,000 after acquiring an additional 2,662 shares in the last quarter. 97.67% of the stock is currently owned by hedge funds and other institutional investors.

Ultragenyx Pharmaceutical Stock Down 0.8 %

RARE opened at $41.10 on Friday. The stock has a market cap of $3.42 billion, a PE ratio of -5.12 and a beta of 0.60. The business has a 50 day moving average of $41.29 and a 200-day moving average of $45.06. Ultragenyx Pharmaceutical has a 52 week low of $31.52 and a 52 week high of $54.56.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($2.03) EPS for the quarter, missing analysts’ consensus estimates of ($1.72) by ($0.31). The firm had revenue of $108.83 million during the quarter, compared to analysts’ expectations of $116.03 million. Ultragenyx Pharmaceutical had a negative net margin of 138.58% and a negative return on equity of 425.63%. The company’s revenue for the quarter was up 8.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($2.33) EPS. Equities analysts anticipate that Ultragenyx Pharmaceutical will post -6.43 EPS for the current year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.